<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0036-3634</journal-id>
<journal-title><![CDATA[Salud Pública de México]]></journal-title>
<abbrev-journal-title><![CDATA[Salud pública Méx]]></abbrev-journal-title>
<issn>0036-3634</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0036-36342002000200011</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Clinicians and the economic evaluation of health]]></article-title>
<article-title xml:lang="es"><![CDATA[Los clínicos y la evaluación económica de la salud]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Merino]]></surname>
<given-names><![CDATA[José G]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,University of Florida Health Sciences Center Department of Neurology ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2002</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2002</year>
</pub-date>
<volume>44</volume>
<numero>2</numero>
<fpage>153</fpage>
<lpage>157</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0036-36342002000200011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0036-36342002000200011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0036-36342002000200011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Papers dealing with the economic evaluation of health care have proliferated in the clinical literature. They provide an evidence-based element to help policy makers allocate resources among competing projects. These studies are generally done from a the perspective of a health provider (public or practice) or a public health professional, they do not take into account the special nature of the patient-physician relationship. The value of these studies for a clinician caring for an individual patient is questioned because the perspective used and the values measured represent those of society or a health provider, not those of patients. In addition, since cost-effectiveness analysis fails to take into account important societal ethical beliefs that are relevant to the care of individuals, its application to individual care is limited. Physicians should use these analyses when working as private or public policy makers, not as clinicians.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Recientemente han proliferado en la literatura clínica estudios de la evaluación económica de la atención a la salud. Este tipo de análisis permite aplicar los principios de la atención a la salud, basada en la evidencia de decisiones que afectan la distribución de recursos entre proyectos alternativos. El hecho de que estos estudios generalmente se llevan a cabo desde una perspectiva de salud pública o de la de un organismo proveedor de servicios (público o privado), y que no toman en cuenta las características particulares de la relación médico-paciente, hace que su valor para un médico que se ocupa de un paciente individual sea limitado. En este ensayo se cuestiona la utilidad de estos estudios en la práctica clínica cotidiana. Un problema fundamental es que los valores medidos en los análisis económicos son los de la sociedad en su conjunto o los de un proveedor de salud, no los de un paciente específico. Adicionalmente, los estudios de costo-efectividad no toman en cuenta creencias éticas de la sociedad que son relevantes para el cuidado de los individuos. Los resultados de estos estudios son muy importantes para los que determinan las políticas de salud (incluso para los clínicos cuando actúan como administradores de recursos para la salud), pero no en la interacción clínica entre un médico y un paciente.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[economics medical]]></kwd>
<kwd lng="en"><![CDATA[cost effectiveness analysis]]></kwd>
<kwd lng="en"><![CDATA[medical ethics]]></kwd>
<kwd lng="en"><![CDATA[public health]]></kwd>
<kwd lng="en"><![CDATA[health policy]]></kwd>
<kwd lng="es"><![CDATA[economía médica]]></kwd>
<kwd lng="es"><![CDATA[análisis de costo-efectividad]]></kwd>
<kwd lng="es"><![CDATA[ética médica]]></kwd>
<kwd lng="es"><![CDATA[salud pública]]></kwd>
<kwd lng="es"><![CDATA[política de salud]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="left"><font size="2"><b><a name="tx"></a>ENSAYO</b></font></p>     <p align="left">&nbsp;</p>     <p align="center"><b><font size=5> Clinicians and the economic evaluation of health</font></b></p>     <P align="left">&nbsp;     <P align="center"><font size="3">Jos&eacute; G Merino, MD, M Phil.<sup>(<a href="#nt">1</a>)</sup></font>     <p align="left">&nbsp;     <p align="left">&nbsp;</p>     <p align="left"><font size="3"> Merino JG.    <br> Clinicians and the economic evaluation of health.    <br> Salud Publica Mex 2002;44:153-157.    ]]></body>
<body><![CDATA[<br> <b> The English version of this paper is available too  at: <a href="http://www.insp.mx/salud/index.html"> http://www.insp.mx/salud/index.html</a></b></font></p>     <P align="left"><font size="3"><b>Abstract    <br>   </b>Papers dealing with the economic evaluation of health care have proliferated    in the clinical literature. They provide an evidence-based element to help policy    makers allocate resources among competing projects. These studies are generally    done from a the perspective of a health provider (public or practice) or a public    health professional, they do not take into account the special nature of the    patient-physician relationship. The value of these studies for a clinician caring    for an individual patient is questioned because the perspective used and the    values measured represent those of society or a health provider, not those of    patients. In addition, since cost-effectiveness analysis fails to take into    account important societal ethical beliefs that are relevant to the care of    individuals, its application to individual care is limited. Physicians should    use these analyses when working as private or public policy makers, not as clinicians.    The English version of this paper is available too at: <a href="http://www.insp.mx/salud/index.html">    http://www.insp.mx/salud/index.html</a>    <br> Key words: economics medical; cost effectiveness  analysis; medical ethics; public health; health policy</font>     <P align="left">&nbsp;     <P align="left"><font size="3">Merino JG.    <br> Los cl&iacute;nicos y la evaluaci&oacute;n econ&oacute;mica de la salud.    <br> Salud Publica Mex 2002;44:153-157.    <br> <b> El texto completo en ingl&eacute;s de este art&iacute;culo tambi&eacute;n</b></font> <b> <font size="3">est&aacute; disponible en: <a href="http://www.insp.mx/salud/index.html"> http://www.insp.mx/salud/index.html</a></font> </b>     <P align="left"><font size="3"><b>Resumen    ]]></body>
<body><![CDATA[<br> </b>Recientemente han proliferado en la literatura cl&iacute;nica  estudios de la evaluaci&oacute;n econ&oacute;mica de la atenci&oacute;n a la  salud. Este tipo de an&aacute;lisis permite aplicar los principios de  la atenci&oacute;n a la salud, basada en la evidencia de decisiones  que afectan la distribuci&oacute;n de recursos entre proyectos  alternativos. El hecho de que estos estudios generalmente  se llevan a cabo desde una perspectiva de salud p&uacute;blica o de  la de un organismo proveedor de servicios (p&uacute;blico o  privado), y que no toman en cuenta las caracter&iacute;sticas  particulares de la relaci&oacute;n m&eacute;dico-paciente, hace que su valor  para un m&eacute;dico que se ocupa de un paciente individual sea  limitado. En este ensayo se cuestiona la utilidad de  estos estudios en la pr&aacute;ctica cl&iacute;nica cotidiana. Un problema  fundamental es que los valores medidos en los an&aacute;lisis  econ&oacute;micos son los de la sociedad en su conjunto o los de  un proveedor de salud, no los de un paciente espec&iacute;fico.  Adicionalmente, los estudios de costo-efectividad no  toman en cuenta creencias &eacute;ticas de la sociedad que  son relevantes para el cuidado de los individuos. Los resultados  de estos estudios son muy importantes para los que  determinan las pol&iacute;ticas de salud (incluso para los cl&iacute;nicos  cuando act&uacute;an como administradores de recursos para la  salud), pero no en la interacci&oacute;n cl&iacute;nica entre un m&eacute;dico y un  paciente. El texto completo en ingl&eacute;s de este art&iacute;culo  tambi&eacute;n est&aacute; disponible en: <a href="http://www.insp.mx/salud/index.html"> http://www.insp.mx/salud/index.html</a>    <br> Palabras clave: econom&iacute;a m&eacute;dica; an&aacute;lisis de  costo-efectividad; &eacute;tica m&eacute;dica; salud p&uacute;blica; pol&iacute;tica de salud</font>     <p align="left">&nbsp;</p>     <p align="left">&nbsp;</p>     <p align="left"><b><font size="6">A</font></b><font size="3"> <SUB>     </SUB>s a practicing physician I have been intrigued by the proliferation of papers dealing with the  economic evaluation of health care in clinical journals.  This proliferation reflects a growing awareness  among physicians, health care policy makers and the  general public that the resources available for health care  are limited and that for every dollar spent in one  project, health related or otherwise, other programs have to  be foregone (there is an opportunity cost attached to  every allocation decision). Recognizing this quandary  the question that arises is: should a physician alter  her pattern of clinical practice based on the results  of published economic evaluations of health care?  Should a physician working in the clinic apply to  individual patients the findings of an instrument designed  to help policy makers (physicians and otherwise)  set priorities for the allocation of resources  among competing projects? If this is not the case, what is  the benefit of having these studies published in  general clinical journals? At a more fundamental level, is  there a role for &quot;bed-side&quot;  economics?<SUP>1</SUP> Should individual physicians be providing care based on  considerations other than the best interest of the patient, such as  societal good? To address these questions this paper  will examine what cost-effectiveness analysis is and  what it means, some of the assumptions that go into an  economic evaluation, and ways that these can be used  by physicians involved with decision making at  different levels, from micro to macro.</font></p>     <P align="center">&nbsp;     <P align="center"><font size="4">Economic evaluation of health care</font>     <P align="left"><font size="3">Cost-effectiveness analysis (CEA) is a powerful  analytical technique that measures the health  benefit that is obtained from a given expenditure. By  comparing outcomes in relation to costs, CEA helps  decision-makers determine which health interventions  would optimize health outcomes given a limited  budget. All forms of economic evaluations consider costs in  a similar manner, however they differ on how  outcomes are measured. In its classical form, CEA measures  outcomes in terms of natural units, such as mg/dl of  cholesterol or years of life gained. In a variation of  this approach, traditionally called cost-utility  analysis (CUA) but increasingly referred to as CEA in  the literature (and in this paper), the effectiveness  of health interventions is measured in common  units of health related value, such as the quality  adjusted life year (QALY). These measures are based on  preferences expressed by groups of patients or the  public through the assignment of subjective utility values  to specific health states.<SUP>2</SUP> Several techniques, such  as the standard gamble and the time trade off  models, are used to obtain these utility  values.<SUP>3</SUP> Current recommendations emphasize the use of CUA  approach when performing cost-outcome  studies,<SUP>4</SUP> and the most commonly used outcome measure in this type  of analysis is the QALY.<SUP>3</SUP> QALYs incorporate three  factors: the size of quality improvement that a given  treatment or diagnostic intervention produces, the  duration of the health improvement, and the number of  persons that can be expected to benefit from the  intervention.<SUP>2</SUP> </font>     <P align="left">     <font size="3">     Textbooks<SUP>3</SUP> and  guidelines<SUP>4</SUP> to help the clinician evaluate the technical and statistical quality of a  CEA have been published recently, they will likely lead  to an increase in the number of cost-effectiveness  studies published in the clinical literature. To assess the  relationship between CEA studies and clinical  decision making it is worthwhile to explores some  components and underlying assumptions that go into CEA  studies: the concept of worth and who decides how much  something is worth, the importance of the  perspective used in the cost-outcome analysis, the different  perspectives of those involved in health related  decision making, and the issue of values for different  decision makers.</font>     <P align="center">&nbsp;     ]]></body>
<body><![CDATA[<P align="center"><font size="4">Assumptions of cost-effectiveness analysis and their relevance to the clinic</font>     <P align="left"><font size="3">What is the meaning of &quot;cost-effective&quot;?  Different uses of the term have led to great confusion in  the literature. In an attempt to clarify the issue,  Doubliet<SUP>5</SUP> has identified four ways in which the term is  currently used: a) as a synonym for cost savings; b) as a  synonym for clinical effectiveness, c) when referring to  cost savings that lead to an equal or better health  outcome, and d) when an intervention leads to the  production of an additional benefit that is felt to be worth the  extra cost. He agrees with the last two uses of the  term. Allan Detsky<SUP>6</SUP> favors the last definition, and he  refers to such an intervention as &quot;economically  attractive&quot; because the term &quot;implies a cost effectiveness  ratio below the threshold that society is willing to bear  for health gains.&quot;<SUP>6</SUP> </font>     <P align="left">     <font size="3">     The concept of &quot;worth the extra cost&quot; is key  to understanding the role that economic evaluations  play in the decision making process. A technically  adequate CEA informs the policy maker of how many  dollars have to be spent to obtain a given outcome  (measured in QALYs) for the intervention being evaluated. A  CEA study does not determine whether the benefits  are worth the cost or not. In that sense, it is a  descriptive and not a prescriptive instrument. The decision of  how much each QALY is worth implies a difficult  value judgement. Since society will ultimately pay for  the </font><font size="3"> benefits (through taxation or payment of insurance premiums and &quot;out of pocket&quot; expenses), society  must make this judgement through political means.  Strategies to aid in determining what is a &quot;good value  for the money&quot; have been established  recently,<SUP>7</SUP> but they remain  controversial.<SUP>8</SUP> Since the value placed on  a given outcome must be determined by society, it  follows that the decision of how much should be spent  to obtain that outcome cannot be determined by a  physician interacting with a particular patient.</font>     <P align="left">     <font size="3">     A related issue is the question of the  perspective that is used in CEA. The point of view used in the  CEA will determine which costs and benefits are  evaluated. Recent recommendations<SUP>4</SUP> stress the value of  performing economic evaluations from a societal  perspective because the goal of using economic evaluations to  set health policy should be to maximize the health of  the population, given a fixed budget. Choosing the  societal approach implies that the costs will be borne,  and the benefits enjoyed, by society in  general,<SUP>9</SUP> assuming that through a redistributive process those who  benefit from any intervention may potentially  compensate those who lose. The application of the  intervention is thus a public policy issue. A CEA done from the  point of view of society has limited applicability to an  individual case, since the risk to each individual is  greater than the risk perceived from a population  perspective<SUP>9</SUP> because each person is unlikely to bear the  average burden and receive the average  benefit.<SUP>10</SUP> Economic evaluations of health are analytical tools that help  assess the feasibility of various competing health  interventions at the group level. Clinicians are  primarily concerned with outcomes at the individual level.</font>     <P align="left">     <font size="3">     When dealing with individual patients,  physicians are more concerned with clinical rather than cost  effectiveness.<SUP>11</SUP> Physicians give more weight to the  personal concerns of patients when considering them  as individuals and more weight to general criteria of  effectiveness when considering them as a  group<SUP>12</SUP> Patient centered care should reflect the preference of  patients, not those of society or other groups (government,  other health care providers).</font>     <P align="left">     <font size="3">     An inescapable question that arises when  measuring values is, whose values should be  measured? Should the values of patients affected with a  disease be used? After all, they have first hand experience  of the quality of life associated with that particular  illness. However, the value they assign to an  intervention that addresses their disease may be biased  by self-interest (the same could be said for physicians  who specialize in treating that particular condition).  Should the public at risk be asked about the utility value  that they associate with a given intervention (for  example, asking young women to give their preferences  regarding breast cancer screening)? Some analysts have  expressed doubts regarding the stability, and hence  the reliability and the validity, of values expressed by  respondents who have not experienced a particular  disease state.<SUP>13</SUP> Should a representative sector of  society decide? The choice of who to ask will determine  the utility associated with a given intervention, and it  will seldom reflect the values and preferences of a  particular patient.</font>     <P align="left">     <font size="3">     Applying societal values to the care of an  individual is problematic. The patient-physician  relationship is built on the fundamental premise that the  interests of the patient are the major concern of the  physician. By focusing on the interests of a group or of society  as a whole, economic evaluations fail to incorporate  this central premise. In addition, some critics of  CEA hold that it fails to take into account important  societal ethical beliefs. In particular Menzel identified  three major values whose importance to society, as  manifested in empirical studies, is neglected by  CEA.<SUP>2</SUP> The first one is the fact that to promote equality our  society strives to treat those who are disadvantaged.  Those who are severely ill are given priority with respect  to treatment. Second, our society believes that  when identifiable patients face a great risk of avoidable  death they have a unique claim on resources (rule of  rescue) even when this does not lead to societal well being  (as opposed to the well being of the individual and  his family). The usual example used in this case is the  child trapped in a well. Lastly, most people would not  choose to withhold treatment from patients who are  already burdened with a lower potential for overall  health. Thus, people with paraplegia are entitled to the  same care as neurologically intact patients even if the  expected utility value of their expected clinical health  status is lower. Methods have recently been proposed to  combine patient and public values into CEA to correct  for these biases.<SUP>2, 14</SUP> Physicians are faced daily with  patients to whom these principles apply. The fact that  these factors are often not taken into account in  CEA should make clinicians wary of generalizing the  results of economic evaluations to their encounters  with patients.</font>     <P align="left">     <font size="3">     The perspective of the decision-maker (for  example a clinician working with a patient as opposed  to a public health physician working with a  population) is also important, and it exemplifies the conflict  that exists between two different conceptions of health  care. On the one hand, a liberal tradition focuses on the  protection of individual rights and interests and in  the pursuit of the individual good.<SUP>15</SUP> This concept  goes hand in hand with the perception of the  physician </font><font size="3"> having an ethical responsibility to act on her  patient's best interests regardless of the costs to society. On  the other hand, a civic republican tradition based on  the idea of community, solidarity, and mutual  responsibility is built on the premise that the improvement  of societal well being leads to an improvement of the  well being of all individuals in  society<SUP>15</SUP> Under this civic tradition a health care worker would have to consider  the interests of society to be equal to, or more  important than, those of the individual when determining  what course of action to take with any given patient.  Some have advocated a framework that puts  individual autonomy and social equity into focus  simultaneously, as embodied in the concept of  citizenship.<SUP>15</SUP> However, Danis and Churchill argue that &quot;when there is  a conflict between what is best for society and what  is best for the patient, the physician should  respect self determination and treat according to the  patient's wishes, so long as the treatment option is available  and expected to yield some benefit.&quot;<SUP>16</SUP> </font>     <P align="left">     <font size="3">     Eddy<SUP>17, 18 </SUP>sees an inherent conflict between  these two positions as regards health care. For him, a  decision-maker working within a public health  perspective wants to allocate scarce resources as efficiently  as possible across all patients. An individual  clinician wants to allocate resources to best serve his  patient. The decision-maker and the clinician are both  acting towards a similar goal; optimizing the health care  provided to those they serve. However, their  constituencies are different. The public health physician looks  at the problem from the top-down; he is interested  in optimizing health for the population as a whole,  and would recommend measures that aim to fulfill  this need. The expectation is that by implementing  measures that optimize the health for the population,  all individuals will have better odds of a healthy life.  The clinician, on the other hand, looks at the problem  from a narrower point of view, that of a particular  patient. Eddy maintains that: &quot;The plain fact is that the  practitioner's particular role in delivering health care  virtually precludes him or her from being able to  make resource allocation decisions  accurately.&quot;<SUP>18</SUP> The reason for this is that a physician faced with an  individual patient has to try to give the best odds to that  patient. The idea of implementing measures that improve  societal well being cannot apply.</font>     <P align="center">&nbsp;     ]]></body>
<body><![CDATA[<P align="center"><font size="4">Utility of economic evaluations to the clinician</font>     <P align="left"><font size="3">Methodologically sound economic evaluations of health care can help policy makers allocate  resources to those programs that will give the greatest  health benefit per dollar to society. CEA is only one  element in the decision making process; allocation  determinations are influenced by other political and  economic considerations.</font>     <P align="left">     <font size="3">     Physicians can play two roles in the provision  of health care, albeit not simultaneously. At the  micro level they act as clinicians interacting with  particular patients. At this level CEA studies published in the  literature are not useful, for the reasons previously  discussed. In fact, some authors consider the use of  QALYs in clinical decision making  dangerous.<SUP>19</SUP> When dealing with a patient, clinicians have the fiduciary  obligation to act on the patient's best interest, within  the constraints set by society. Unilateral rationing  by the physician at the bedside has been considered  morally unacceptable.<SUP>20</SUP> Clinical practice guidelines  that maximize cost-effectiveness for individual  patients often do not maximize cost-effectiveness for  populations of patients, and vice versa.<SUP>21</SUP> </font>     <P align="left">     <font size="3">     At the departmental, hospital or  governmental level physicians can act as policy makers, and thus  have to allocate resources among competing projects.  When acting in this capacity, physicians can combine  practical clinical expertise with the results of studies  that evaluate the economic viability of the various  alternatives. They should become familiar with the  concepts that underlie such studies, and should be able to  evaluate their quality. This use of CEA will lead to  evidence-based budgetary limits under which  clinicians will practice. The dual role of physicians -as  clinicians and as policy makers- justifies the publication of  CEA in the clinical literature.</font>     <P align="center">&nbsp;     <P align="center"><font size="4">Conclusions</font>     <P align="left"><font size="3">CEA has limited applicability at the bedside.  There are several reasons for this: The clinician cannot  make value judgements for society; the perspective used  in well designed, technically adequate CEA is not that  of the individual patient; the preferences and values  used in a CEA may reflect those of society, or the health  care system, or the insurance company but not those  of someone afflicted by the disease in question; CEA  fails to take into account societal values that are relevant  to an individual clinical encounter.<SUP>1,  22-24</SUP> Economic evaluations of health care are designed to help the  policy maker allocate resources, not care for individual  patients. The physician should use the results of  CEA when acting not as a clinician caring for a patient  but as a policy maker allocating a budget among  competing objectives.</font>     <p align="left">&nbsp;</p>     <p align="center"><font size="4"> Acknowledgments</font></p>     <P align="left"><font size="3">I would like to thank Jeff Hoch, Ph D, and Julieta  Caride, MBA for their comments during the  preparation of the manuscript.</font>     ]]></body>
<body><![CDATA[<P align="center">&nbsp;     <P align="center"><font size="4">References</font>     <!-- ref --><P align="left"><font size="3">1. Walter SD, Hurley JE, Labelle RJ, Sackett DL. Clinical rounds for  non-clinicians: Some impressions. J Clin Epidemiol 1990;43:612-618.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179133&pid=S0036-3634200200020001100001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">2. Menzel P, Gold MR, Nord E, Pinto-Prades JL, Richardson J, Ubel P.  Toward a broader view of values in cost-effectiveness analysis of  health. Hastings Cent Rep 1999;29(3):7-15.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179134&pid=S0036-3634200200020001100002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">3. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods  for economic evaluation of health care programmes.  (2<SUP>nd</SUP> ed Oxford. Oxford: University Press, 1999.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179135&pid=S0036-3634200200020001100003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">4. Drummond MF, Jefferson TO, and the BMJ Economic Evaluation  Working Party. Guidelines for authors and peer reviewers of economic  submissions to the BMJ. BMJ. 1996;313:275-283.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179136&pid=S0036-3634200200020001100004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">5. Doubliet P, Weinstein MC, McNeil BJ. Use and misuse of the term  &quot;cost effective&quot; in medicine. N Engl J Med 1986;314:253-256.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179137&pid=S0036-3634200200020001100005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">6. Detsky AS. Terminology I would like to see disappear. Am Heart  J 1999;137:S51-S52.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179138&pid=S0036-3634200200020001100006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">7. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a  new technology have to be to warrant adoption and utilization? Tentative  guidelines for using clinical and economic evaluations. Can Med Assoc  J 1992;146:473-481.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179139&pid=S0036-3634200200020001100007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">8. Gafni A, Birch S. Guidelines for the adoption of new technologies:  A prescription for uncontrolled growth in expenditures and how to  avoid the problem. Can Med Assoc J 1992;148:913-917.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179140&pid=S0036-3634200200020001100008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">9. Asch DA. Choices for individual patients vs.groups. N Engl J  Med 1990:323:922.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179141&pid=S0036-3634200200020001100009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">10. Asch DA, Hershey JC. Why some health policies don't make sense  at the bedside. Ann Intern Med 1995;122:846-850.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179142&pid=S0036-3634200200020001100010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">11. Gifford F. Outcomes research and practice guidelines: Upstream  issues for downstream users. Hastings Cent Rep 1996;26(2):38-44.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179143&pid=S0036-3634200200020001100011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">12. Redelmeier DA, Tversky A. Discrepancy between medical  decisions for individual patients and for groups. N Engl J Med 1990;322:1162-1164.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179144&pid=S0036-3634200200020001100012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">13. Shiell A, Hawe P, Seymour J. Values and preferences are not  necessarily the same. Health Econ 1997;6:515-518.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179145&pid=S0036-3634200200020001100013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">14. Ubel PA, Richardson J, Menzel P. Societal value, the person  trade-off, and the dilemma of whose values to measure for cost-effectiveness  analysis. Health Econ 2000;9:127-136.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179146&pid=S0036-3634200200020001100014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">15. Jennings B. Beyond distributive justice in Health Reform. Hastings  Cent Rep 1996;26(6):14-16.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179147&pid=S0036-3634200200020001100015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">16. Danis M, Churchill LR. Autonomy and the common weal. Hastings  Cent Rep 1991;21(1):25-31.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179148&pid=S0036-3634200200020001100016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">17. Eddy DM. Cost-effectiveness analysis: Will it be accepted?  JAMA 1992;268:132-136.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179149&pid=S0036-3634200200020001100017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">18. Eddy DM. Cost-effectiveness analysis: A conversation with my  father. JAMA 1992;267:1669-1675.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179150&pid=S0036-3634200200020001100018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">19. LaPuma J, Lawlor E. Quality adjusted life years: Ethical implications  for physicians and policymakers. JAMA 1990;263:2917-2921.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179151&pid=S0036-3634200200020001100019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">20. Sulmasy DP. Physicians, cost control and ethics. Ann Intern  Med 1992;116:920-926.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179152&pid=S0036-3634200200020001100020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">21. Granata AV, Hillman AL. Competing practice guidelines: Using  cost-effectiveness analysis to make optimal decisions. Ann Intern  Med 1998;128:56-63.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179153&pid=S0036-3634200200020001100021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">22. Detsky AS, Naglie IG. A clinician's guide to cost effectiveness  analysis. Ann Intern Med 1990;113:147-154.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179154&pid=S0036-3634200200020001100022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">23 Dyer AR. Patients, not costs, come first. Hastings Cent Rep  1986;16(2): 5-6.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179155&pid=S0036-3634200200020001100023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P align="left"><font size="3">24. Angell M. The doctor as a double agent. Kennedy Inst Ethics J  1993;3: 279-286.</font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9179156&pid=S0036-3634200200020001100024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p align="left">&nbsp;</p>     <p align="left">&nbsp;</p>     <p align="left"><font size="3"> This paper was made possible in part by Fisher Family/Heart and Stroke Foundation of Ontario Research Fellowship Award #4528.</font></p>     <P align="left"><font size="3"><a name="nt"></a>(<a href="#tx">1</a>)     Department of Neurology. University of Florida Health Sciences Center/Jacksonville, Florida, Estados Unidos de Am&eacute;rica.</font>     ]]></body>
<body><![CDATA[<P align="left">&nbsp;     <P align="center"><font size="3"><B>Received on</B>: January 11, 2001 <font FACE="Symbol">·</font> <B>Accepted on:  </B>October 10, 2001    <br> Address reprint requests to: Dr Jos&eacute; G Merino. Department of Neurology, University of Florida Health Sciences Center-Jacksonville, 580 West  Eight Street, Plaza I, 9<SUP>th</SUP> floor, Jacksonville, FL 32209-6511, E.U.A.    <br> E-mail: <a href="mailto:jose.merino@jax.ufl.edu"> jose.merino@jax.ufl.edu</a></font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Hurley]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Labelle]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sackett]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical rounds for non-clinicians: Some impressions]]></article-title>
<source><![CDATA[J Clin Epidemiol]]></source>
<year>1990</year>
<volume>43</volume>
<page-range>612-618</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menzel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Nord]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto-Prades]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ubel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Toward a broader view of values in cost-effectiveness analysis of health]]></article-title>
<source><![CDATA[Hastings Cent Rep]]></source>
<year>1999</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>7-15</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[O'Brien]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddart]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<source><![CDATA[Methods for economic evaluation of health care programmes]]></source>
<year>1999</year>
<edition>2</edition>
<publisher-loc><![CDATA[OxfordOxford ]]></publisher-loc>
<publisher-name><![CDATA[University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Jefferson]]></surname>
<given-names><![CDATA[TO]]></given-names>
</name>
</person-group>
<collab>BMJ Economic Evaluation Working Party</collab>
<article-title xml:lang="en"><![CDATA[Guidelines for authors and peer reviewers of economic submissions to the BMJ]]></article-title>
<source><![CDATA[BMJ.]]></source>
<year>1996</year>
<volume>313</volume>
<page-range>275-283</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doubliet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstein]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[McNeil]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use and misuse of the term "cost effective" in medicine]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1986</year>
<volume>314</volume>
<page-range>253-256</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Detsky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Terminology I would like to see disappear]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1999</year>
<volume>137</volume>
<page-range>S51-S52</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laupacis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Feeny]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Detsky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Tugwell]]></surname>
<given-names><![CDATA[PX]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations]]></article-title>
<source><![CDATA[Can Med Assoc J]]></source>
<year>1992</year>
<volume>146</volume>
<page-range>473-481</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gafni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Birch]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem]]></article-title>
<source><![CDATA[Can Med Assoc J]]></source>
<year>1992</year>
<volume>148</volume>
<page-range>913-917</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asch]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Choices for individual patients vs groups]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1990</year>
<page-range>323:922</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asch]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Hershey]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Why some health policies don't make sense at the bedside]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1995</year>
<volume>122</volume>
<page-range>846-850</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gifford]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Outcomes research and practice guidelines: Upstream issues for downstream users]]></article-title>
<source><![CDATA[Hastings Cent Rep]]></source>
<year>1996</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>38-44</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Redelmeier]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Tversky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Discrepancy between medical decisions for individual patients and for groups]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1990</year>
<volume>322</volume>
<page-range>1162-1164</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shiell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hawe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Seymour]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Values and preferences are not necessarily the same]]></article-title>
<source><![CDATA[Health Econ]]></source>
<year>1997</year>
<volume>6</volume>
<page-range>515-518</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ubel]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Menzel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis]]></article-title>
<source><![CDATA[Health Econ]]></source>
<year>2000</year>
<volume>9</volume>
<page-range>127-136</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jennings]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beyond distributive justice in Health Reform]]></article-title>
<source><![CDATA[Hastings Cent Rep]]></source>
<year>1996</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>14-16</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Churchill]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autonomy and the common weal]]></article-title>
<source><![CDATA[Hastings Cent Rep]]></source>
<year>1991</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-31</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eddy]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness analysis: Will it be accepted?]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1992</year>
<volume>268</volume>
<page-range>132-136</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eddy]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness analysis: A conversation with my father]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1992</year>
<volume>267</volume>
<page-range>1669-1675</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LaPuma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lawlor]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Quality adjusted life years: Ethical implications for physicians and policymakers]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1990</year>
<volume>263</volume>
<page-range>2917-2921</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sulmasy]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Physicians, cost control and ethics]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1992</year>
<volume>116</volume>
<page-range>920-926</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granata]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Hillman]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Competing practice guidelines: Using cost-effectiveness analysis to make optimal decisions]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1998</year>
<volume>128</volume>
<page-range>56-63</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Detsky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Naglie]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A clinician's guide to cost effectiveness analysis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1990</year>
<volume>113</volume>
<page-range>147-154</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dyer]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Patients, not costs, come first]]></article-title>
<source><![CDATA[Hastings Cent Rep]]></source>
<year>1986</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>5-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The doctor as a double agent]]></article-title>
<source><![CDATA[Kennedy Inst Ethics J]]></source>
<year>1993</year>
<volume>3</volume>
<page-range>279-286</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
